The recently published results from the MyPathway trial26,45 studying treatment with trastuzumab and pertuzumab in colorectal cancer showed an overall response rate of 40% in patients without KRAS mutations, confirming preliminary data that HER2 testing could be integrated in future guidelines for biomarker testing in other tumor types, such as colorectal,44,46 salivary, bladder, and biliary cancers. Here, KRAS is linked to neoplasm.